Stock listing

Repligen Corporation

Selected listing: R2GE34 · BMFBOVESPA · BRL · BR

Repligen Corporation (B3:R2GE34), Health Technology. Latest release Oct 6, 2026: Repligen Completes Acquisition of BioLife Solutions.

R2GE34:BMFBOVESPABRLBRUpdated September 25, 2026

Ticker: B3:R2GE34
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: B3
Currency: BRL

About Repligen Corporation

Repligen Corporation (Ticker: RGEN) is a public company based in America, specializing in bioprocessing technologies for the global life sciences industry. The company's offerings support the production of biologics, including monoclonal antibodies and gene therapies.

Latest news from Repligen Corporation

Repligen Completes Acquisition of BioLife Solutions

October 6, 2026

Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference

August 26, 2026

Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

July 28, 2026

Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media

July 22, 2026

Repligen to Report Second Quarter 2026 Financial Results

July 15, 2026

All Repligen Corporation news →

Events

Replays

Repligen Corporation (RGEN) Q2 2026 Earnings Call
Tue, Jul 28, 2026 · 08:00 AM ET
Watch
Repligen Corporation (RGEN) Q1 2026 Earnings Call
Tue, May 05, 2026 · 08:00 AM ET
Watch
Repligen Corporation (RGEN) Q4 2025 Earnings Call
Tue, Feb 24, 2026 · 08:30 AM ET
Watch

Research Repligen Corporation

Repligen Corporation company profile

View the public company page for Repligen Corporation on 6ix.

Repligen Corporation news

Read company news and market updates connected to Repligen Corporation.

Repligen Corporation investor events

Find investor webinars, events, and replay context for Repligen Corporation.